Literature DB >> 25267967

Tenofovir-associated Fanconi syndrome in a patient with chronic hepatitis B.

Michael Samarkos1, Vassileios Theofanis2, Irene Eliadi2, John Vlachogiannakos3, Aris Polyzos2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25267967

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN： 1841-8724            Impact factor:   2.008


× No keyword cloud information.
  7 in total

Review 1.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

2.  Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.

Authors:  Andrew Ustianowski; Joop E Arends
Journal:  Infect Dis Ther       Date:  2015-06-02

3.  Early Onset of Tenofovir-Related Fanconi Syndrome in a Child with Acute Hepatitis B: A Case Report and Systematic Review of Literature.

Authors:  Renato Pascale; Viola Guardigni; Lorenzo Badia; Francesca Volpato; Pierluigi Viale; Gabriella Verucchi
Journal:  Case Reports Hepatol       Date:  2017-11-15

4.  Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.

Authors:  Jing Zhou; Yue-Ying Liu; Jiang-Shan Lian; Li-Fang Pan; Jian-Le Yang; Jian-Rong Huang
Journal:  Chin Med J (Engl)       Date:  2017-04-20       Impact factor: 2.628

Review 5.  Adverse effects of oral antiviral therapy in chronic hepatitis B.

Authors:  Bircan Kayaaslan; Rahmet Guner
Journal:  World J Hepatol       Date:  2017-02-18

6.  Effect of tenofovir on renal function in patients with chronic hepatitis B.

Authors:  Woo Jin Jung; Jae Young Jang; Won Young Park; Soung Won Jeong; Hee Jeong Lee; Sang Joon Park; Sae Hwan Lee; Sang Gyune Kim; Sang-Woo Cha; Young Seok Kim; Young Deok Cho; Hong Soo Kim; Boo Sung Kim; Suyeon Park; Baigal Baymbajav
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

7.  A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.

Authors:  Rong-Yue Liang; Jing-Hang Xu; Chong-Wen Si; Sa Wang; Jia Shang; Zu-Jiang Yu; Qing Mao; Qing Xie; Wei Zhao; Jun Li; Zhi-Liang Gao; Shan-Ming Wu; Hong Tang; Jun Cheng; Xin-Yue Chen; Wen-Hong Zhang; Hao Wang; Zhong-Nan Xu; Ling Wang; Jun Dai; Yan-Yan Yu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.